RBC Capital Reiterates Outperform on Definium Therapeutics, Maintains $66 Price Target

Benzinga Newsdesk www.benzinga.com Negative 82.0%

Neg 82% Neu 0% Pos 0%

RBC Capital analyst Brian Abrahams reiterates Definium Therapeutics (NASDAQ:DFTX) with a Outperform and maintains $66 price target.